Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with hereditary angioedema

Trial Profile

A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with hereditary angioedema

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs BCX 7353 (Primary)
  • Indications Hereditary angioedema
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ZENITH-1
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 16 Nov 2018 According to a BioCryst Pharmaceuticals media release, data from this study will be presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
    • 16 Nov 2018 Results presented in a BioCryst Pharmaceuticals media release.
    • 04 Sep 2018 Results published in the BioCryst Pharmaceuticals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top